Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025
We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a look at where Sangamo Therapeutics Inc. (NASDAQ:SGMO) stands against the ...
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact
Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.
bovnews6d
Why Did Sangamo Therapeutics Inc (SGMO) Stock Plunge -24.07% Last Week?
Truist has recently raised Sangamo Therapeutics Inc (SGMO) stock to Buy rating, as announced on December 13, 2024, according to Finviz. Earlier, on December 10, 2024, H.C. Wainwright had reiterated ...
Business Wire19d
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) ...
Hosted on MSN23d
Why Is Sangamo Therapeutics Inc. (SGMO) Among the Top CRISPR Stocks to Invest In?
In this article, we are going to take a look at where Sangamo Therapeutics Inc. (NASDAQ:SGMO) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation ...
Morningstar22d
Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends hemophilia pact
Editor's note: A breaking-news bulletin linked to this story inaccurately characterized the number of years that have passed since Sangamo Therapeutics shares lost as much in a single session.
bovnews14d
Sangamo Therapeutics Inc (SGMO) Reported a -256.68% Operating Margin Last Year—What’s the Real Story?
Truist has recently raised Sangamo Therapeutics Inc (SGMO) stock to Buy rating, as announced on December 13, 2024, according to Finviz. Earlier, on December 10, 2024, H.C. Wainwright had reiterated ...
ETF Daily News20d
Sangamo Therapeutics (NASDAQ:SGMO) Given “Buy” Rating at HC Wainwright
Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $49.41 million during the quarter, compared to the consensus estimate ...
The Business Journals22d
Options run thin for Sangamo Therapeutics after Pfizer deal crashes
Pfizer Inc. abruptly ended a key hemophilia A gene therapy collaboration with Sangamo Therapeutics Inc., sending the East Bay biotech company's stock sharply lower as its partnership options thinned.
Did Sangamo Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SGMO
NDAQ:SGMO) Did Sangamo Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ...
ETF Daily News23d
Sangamo Therapeutics (NASDAQ:SGMO) Shares Down 6.3% – Time to Sell?
Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report)’s stock price traded down 6.3% on Monday .The stock traded as low as $2.34 and last traded at $2.40. 1,574,041 shares were traded ...
Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future
Sangamo faces steep drop after Pfizer ends partnership, raising concerns about its hemophilia therapy's future ...